The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial disease ...
Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the first quarter 2026 and ...
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 16.8% and a 48.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Adlai Nortye Ltd.
Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full ...
With an infrastructure in place to market its lone commercial product Ruconest, it made sense in 2019 for Pharming Group to scoop up another rare disease candidate in the same arena. Four years later, ...
Pharming's CEO, Sijmen de Vries, will present on Thursday, June 8 at 10:30 EST / 16:30 CEST. A live webcast and replay of the presentation will be available in the "Upcoming Events" and "News" ...
Fintel on MSN
Pharming Group NV - Depositary receipt (PHAR) price target increased by 43.79% to 25.84
The average one-year price target for Pharming Group N.V. - Depositary Receipt (NasdaqGM:PHAR) has been revised to $25.84 / share. This is an increase of 43.79% from the prior estimate of $17.97 dated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results